Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Patterns of progression and clinical outcomes after first relapse in patients with primary plasma cell leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

SKShaji KumarTHTamer HellouPKPrashant Kapoor

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals poorer outcomes with symptomatic relapses in primary plasma cell leukemia, highlighting the impact of treatment type and venetoclax usage.

Key Points

  • This research aims to describe clinical features and survival outcomes at the time of relapse or disease progression in primary plasma cell leukemia.
  • Retrospective analysis of patients with pPCL at a cancer center from 2006-2024.
  • Reviewed electronic health records for demographics, disease characteristics, treatment, and outcomes.
  • Kaplan-Meier method used for time to next treatment and overall survival analysis using JMP 17.0.1.
  • Median overall survival for the cohort was 39 months with 60% mortality.
  • Asymptomatic relapses had longer median time to next treatment compared to symptomatic relapses.
  • Venetoclax treatment in t(11;14) patients showed a median time to next treatment of 15 months.

Cite This Study

Kumar et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d47chttps://doi.org/10.1182/blood-2025-1036
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Patterns of Progression and Clinical Outcomes After First Progression in Patients With Primary Plasma Cell Leukemia2026 · 1 citations
  2. 2Plasma cell leukemia: A single institution review of cases2025
  3. 3Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients2026
  4. 4Single-Center Experience of Patients with Plasma Cell Leukemia in the Era of New Therapeutics2024
  5. 5Prognostic implications of measurable residual disease and autologous hematopoietic stem cell transplantation in primary plasma cell leukemia in the era of novel agents2025